35 completed, 17 unknown, 8 active not recruiting, 8 recruiting. 24 Phase 3, 20 Phase 2, 13 Not applicable, 11 Phase 4, 2 Phase 1.
Follow Triptorelin: new trials by email Literature Review of Triptorelin trials Research Report on Triptorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) Human chorionic gonadotropin (hCG), Follitropin delta, Triptorelin - Low Ovarian Reserve, Poor Ovarian Response | Phase 3 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | 126 | 2024-09-17 | 2026-09-11 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment Recombinant Luteinizing Hormone (rLH), Recombinant Follicle-Stimulating Hormone (rFSH), Gonadotropin-Releasing Hormone Agonist (GnRH-a) - Infertility, Female, Luteinizing Hormone (LH) | Not applicable | Recruiting | Nanjing University | 590 | 2024-02-01 | 2025-08-19 |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 231 | 2024-01-23 | 2026-02-24 |
| Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer Triptorelin, levonorgestrel-releasing intrauterine system, frozen embryo transfer - Adenomyosis | Not applicable | Completed | Zagazig University | 184 | 2023-12-15 | 2024-09-03 |
| Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes Dydrogesterone, Cetrorelix acetate, Triptorelin - IVF | Phase 3 | Unknown | Beni-Suef University | 387 | 2023-07-15 | 2023-08-02 |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland abiraterone, enzalutamide, docetaxel - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Pfizer | 1083 | 2023-02-13 | 2026-01-29 | |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Elacestrant, Triptorelin, Tamoxifen 20 mg - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 96 | 2023-02-03 | 2026-04-24 |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Olaparib, LHRH agonist - Prostate Cancer, BRCA1 Mutation | Phase 2 | Active not recruiting | Rana McKay, MD | 32 | 2023-02-01 | 2026-07-10 |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel - Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2022-01-25 | 2025-12-04 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Darolutamide, Goserelin Acetate, Leuprolide Acetate - Prostate Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 27 | 2021-03-01 | 2026-07-28 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients Leuprorelin, Goserelin, Triptorelin - Prostatic Neoplasms | Phase 4 | Unknown | Wonju Severance Christian Hospital | 164 | 2020-01-23 | 2021-07-29 |
| Generation of Biological Samples Positive to Triptorelin for Anti-doping Control Triptorelin - Healthy Volunteers | Phase 1 | Completed | Parc de Salut Mar | 2 | 2019-04-26 | 2019-12-11 |
Showing 20 of 74. Sign in to see all of them.
Prostatic Neoplasms (27) · Breast Neoplasms (14) · Infertility (11) · Infertility, Female (5) · Ovarian Hyperstimulation Syndrome (3) · Neoplasm Metastasis (2) · Polycystic Ovary Syndrome (2) · Adenomyosis (1) · Congenital Abnormalities (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometriosis (1) · Fatigue (1) · Fatty Liver (1) · Helping Behavior (1) · Hodgkin Disease (1)
ETOP IBCSG Partners Foundation (6) · Radiation Therapy Oncology Group (3) · Cairo University (2) · Chenshiling (2) · ECOG-ACRIN Cancer Research Group (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Ipsen (2) · Mansoura University (2) · NRG Oncology (2) · Organon and Co (2) · UNICANCER (2) · Universitair Ziekenhuis Brussel (2) · Ain Shams University (1) · Alphamab Jilin Co., Ltd. (1) · American University of Beirut Medical Center (1)
United States (20) · Italy (11) · Canada (9) · Egypt (9) · Belgium (7) · China (6) · Spain (5) · Switzerland (5) · France (4) · United Kingdom (4) · Brazil (2) · Chile (2) · Finland (2) · Germany (2) · Hungary (2)
Jingsong Zhang, MD, PhD (2) · Mohamed S Abdelhafez, Dr (2) · Shi-Ling Chen, M.D., Ph.D. (2) · Ahmed Maged, MD (1) · Alan Pollack, MD, PhD (1) · Alfonso Bermejo, MD (1) · Alicia K Morgans (1) · Alvaro A. Martinez, MD, FACR (1) · Ana M Aldea Perona, Dr (1) · Andrea De Matteis, M.D. (1) · Armando Santoro, MD (1) · Arthur Hung (1) · Barbara Walley, MD, FRCPC (1)
PMID 24881463, PMID 25592642, PMID 26092816, PMID 27044936, PMID 28911092, PMID 29863451, PMID 31618131, PMID 36521078, PMID 40986647, PMID 41637791, PMID 18086795, PMID 18258763, PMID 18309951, PMID 19380451, PMID 19403562, PMID 19516032, PMID 20797824, PMID 21247312, PMID 21736917, PMID 21771987, PMID 22412041, PMID 22429192, PMID 22587997, PMID 23129737, PMID 23394779, PMID 24095609, PMID 25495490, PMID 26523330, PMID 26720025, PMID 27022111, PMID 27092785, PMID 27825388, PMID 30589600, PMID 31164265, PMID 33002438, PMID 33011968, PMID 33934703, PMID 33999161, PMID 34370858, PMID 34667023, PMID 35569466, PMID 35780048, PMID 36493334, PMID 36537742, PMID 36710203, PMID 37008942, PMID 37104748, PMID 38421243, PMID 38979716, PMID 39754976
2004 (2), 2005 (2), 2016 (2), U10CA180820 (2), U10CA180868 (2), P30CA076292 (1), R01CA286127 (1), R01CA300454 (1), U10CA180888 (1), U24CA075362 (1)